Skip to main content Accessibility help
×
Home

Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease

  • George J. Brewer (a1), Fred Askari (a2), Matthew T. Lorincz (a3), Martha Carlson (a4), Michael Schilsky (a5), Karen J. Kluin (a6), Peter Hedera (a7), Paolo Moretti (a8), John K. Fink (a9), Roberta Tankanow (a10), Robert B. Dick (a11) and Julia Sitterly (a12)...

Extract

ABSTRACT

Background: The initial treatment of the neurologic presentation of Wilson's disease is problematic. Penicillamine, used for years on most patients, causes neurologic worsening in up to half of such patients, and half of those who worsen never recover. Zinc, ideal for maintenance therapy, is too slow for these acutely ill patients. We have developed tetrathiomolybdate (TM) for this type of patient, and it has worked well in open label studies. Trientine, another anticopper drug on the market approved for penicillamine intolerant patients, had not been tried in this type of patient. Here, we report on a double blind trial of TM versus trientine in the neurologically presenting Wilson's disease patient. Design and Methods: The study was a double blind design in which patients received either TM plus zinc, or trientine plus zinc, for 8 weeksThis study was originally published in reference 1. Patients were accepted if they presented with neurologic symptoms from Wilson's disease, if they had not been treated longer than 4 weeks with penicillamine or trientine. Patients were followed in the hospital for the 8 weeks of treatment with weekly semiquantitative neurologic and speech examinations, to evaluate possible neurologic worsening. They also had blood and urine studies done weekly. At discharge from hospital they were continued on zinc maintenance therapy, and returned at yearly intervals for 3 years for further evaluation. Results: Twenty-three patients were entered into the trientine arm and 6 reached criteria for neurologic deterioration, while 25 patients were entered into the TM arm and only 1 deteriorated (p < 0.05). One patient on trientine had an adverse event while 7 on TM had adverse events. All adverse events were mild. Four patients in the trientine arm died during follow-up, 3 having shown initial neurologic deterioration, 2 patients in the TM arm died. In those patients who did not deteriorate or die, neurologic and speech recovery over 3 years was good. Interpretation: TM is a superior choice to trientine for the initial therapy of neurologic Wilson's disease.

Copyright

Corresponding author

Correspondence should be addressed to: George J. Brewer, MD, Department of Human Genetics and Department of Internal Medicine, University of Michigan Medical School, 5024 Kresge Bldg. II, Ann Arbor, MI 48109-0534, USA; Ph: +1 734 764 5499; Fax: +1 734 615 2048; Email: brewergj@umich.edu

References

Hide All

References

Akil, M., Schwartz, J.A., Dutchak, D., Yuzbasiyan-Gurkan, V., & Brewer, G.J. (1991). The psychiatric presentations of Wilson's disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 3, 377382.
Askari, F.K., Greenson, J., Dick, R.D., Johnson, V.D., & Brewer, G.J. (2003). Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. The Journal of Laboratory and Clinical Medicine, 142, 385390.
Bremner, I., Mills, C.F., & Young, B.W. (1982). Copper metabolism in rats given di- or trithiomolybdates. Journal of Inorganic Biochemistry, 16, 109119.
Brewer, G.J. (2001). Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management. Boston, MA: Kluwer Academic Publishers.
Brewer, G.J. (2004). Wilson's disease. In: Kasper, D.L., Braunward, E., Fauci, A.S., Hauser, S.L., Longo, D.L., & Jameson, J.L. (eds.), Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill Companies, Inc, pp. 23132315.
Brewer, G.J. (2005a). Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs, 19, 185192.
Brewer, G.J. (2005b). Behavioral abnormalities in Wilson's disease. In: Weiner, W.J., Lang, A.E., & Anderson, K.E. (eds.), Behavioral Neurology of Movement Disorders. Philadelphia: Lippincott, Williams & Wilkins, pp. 262274.
Brewer, G.J. (2006). Novel therapeutic approaches to the treatment of Wilson's disease. Expert Opinion on Pharmacotherapy, 7, 317324.
Brewer, G.J., & Askari, F.K. (2005). Wilson's disease: clinical management and therapy. Journal of Hepatology, 42, S13S21.
Brewer, G.J., & Yuzbasiyan-Gurkan, V. (1992). Wilson disease. Medicine, 71, 139164.
Brewer, G.J., Hill, G.M., Prasad, A.S., Cossack, Z.T., & Rabbani, P. (1983). Oral zinc therapy for Wilson's disease. Annals of Internal Medicine, 99, 314319.
Brewer, G.J., Hill, G., Prasad, A., & Dick, R. (1987a). The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper. Proceedings of the Society for Experimental Biology and Medicine, 184, 446455.
Brewer, G.J., Terry, C.A., Aisen, A.M., & Hill, G.M. (1987b). Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Archives of Neurology, 44, 490493.
Brewer, G.J., Dick, R.D., Yuzbasiyan-Gurkan, V., Tankanow, R., Young, A.B., & Kluin, K.J. (1991). Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Archives of Neurology, 48, 4247.
Brewer, G.J., Yuzbasiyan-Gurkan, V., Johnson, V., Dick, R.D., & Wang, Y. (1993). Treatment of Wilson's disease with zinc XII: dose regimen requirements. The American Journal of the Medical Sciences, 305, 199202.
Brewer, G.J., Dick, R.D., Johnson, V., Wang, Y., Yuzbasiyan-Gurkan, V., Kluin, K., et al. (1994a). Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Archives of Neurology, 51, 545554.
Brewer, G.J., Dick, R.D., Yuzbasiyan-Gurkan, V., Johnson, V., & Wang, Y. (1994b). Treatment of Wilson's disease with zinc. XIII: therapy with zinc in presymptomatic patients from the time of diagnosis. The Journal of Laboratory and Clinical Medicine, 123, 849858.
Brewer, G.J., Johnson, V., Dick, R.D., Kluin, K.J., Fink, J.K., & Brunberg, J.A. (1996). Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Archives of Neurology, 53, 10171025.
Brewer, G.J., Dick, R.D., Johnson, V.D., Brunberg, J.A., Kluin, K.J., & Fink, J.K. (1998). Treatment of Wilson's disease with zinc: XV long-term follow-up studies. The Journal of Laboratory and Clinical Medicine, 132, 264278.
Brewer, G.J., Hedera, P., Kluin, K.J., Carlson, M., Askari, F., Dick, R.B., et al. (2003). Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Archives of Neurology, 60, 379385.
Brewer, G.J., Askari, F., Lorincz, M.T., Carlson, M., Schilsky, M., Kluin, K.J., et al. (2006). Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Archives of Neurology, 63, 521527.
Bull, P.C., Thomas, G.R., Rommens, J.M., Forbes, J.R., & Cox, D.W. (1993). The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature Genetics, 5, 327337.
Fink, J.K., Hedera, P., & Brewer, G.J. (1999). Hepatolenticular degeneration (Wilson's disease). The Neurologist, 5, 171185.
Gooneratne, S.R., Howell, J.M., & Gawthorne, J.M. (1981). An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. The British Journal of Nutrition, 46, 469480.
Hill, G.M., Brewer, G.J., Prasad, A.S., Hydrick, C.R., & Hartmann, D.E. (1987). Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens. Hepatology, 7, 522528.
Hoogenraad, T.U., Koevoet, R., & de Ruyter Korver, E.G. (1979). Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). European Neurology, 18, 205211.
Hoogenraad, T.U., Van Hattum, J., & Van den Hamer, C.J.A. (1987). Management of Wilson's disease with zinc sulfate. Experience in a series of 27 patients. Journal of the Neurological Sciences, 77, 137146.
Mason, J. (1990). The biochemical pathogenesis of molybdenum-induced copper deficiency syndromes in ruminants: towards the final chapter. Irish Veterinary Journal, 43, 1821.
Mills, C.F., El-Gallad, T.T., & Bremner, I. (1981a). Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. Journal of Inorganic Biochemistry, 14, 189207.
Mills, C.F., El-Gallad, T.T., Bremner, I., & Weham, G. (1981b). Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. Journal of Inorganic Biochemistry, 14, 163175.
Scheinberg, I.H., & Sternlieb, I. (1998). Wilson's disease. In: Smith, L.H.J. (ed.), Major Problems in Internal Medicine. Philadelphia: W.B. Saunders Company, pp. 1171.
Schilsky, M.L. (1996). Wilson disease: genetic basis of copper toxicity and natural history. Seminars in Liver Disease, 16, 8395.
Tanzi, R.E., Petrukhin, K., Chernov, I., Pellequer, J.L., Wasco, W., Ross, B., et al. (1993). The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nature Genetics, 5, 344350.
Walshe, J.M. (1956). Penicillamine, a new oral therapy for Wilson's disease. American Journal of Medicine, 21, 487495.
Walshe, J.M. (1982). Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet, 1, 643647.
Yamaguchi, Y., Heiny, M.E., & Gitlin, J.D. (1993). Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochemical and Biophysical Research Communications, 197, 271277.
Yuzbasiyan-Gurkan, V., Grider, A., Nostrant, T., Cousins, R.J., & Brewer, G.J. (1992). Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. The Journal of Laboratory and Clinical Medicine, 120, 380386.

Keywords

Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease

  • George J. Brewer (a1), Fred Askari (a2), Matthew T. Lorincz (a3), Martha Carlson (a4), Michael Schilsky (a5), Karen J. Kluin (a6), Peter Hedera (a7), Paolo Moretti (a8), John K. Fink (a9), Roberta Tankanow (a10), Robert B. Dick (a11) and Julia Sitterly (a12)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed